Protein tyrosine kinases (PTK) play a fundamental role in signal transduction pathways. Deregulated tyrosine kinase activity has been observed in cancer and other proliferative diseases. Therefore, tyrosine kinases are attractive targets for the design of new therapeutic agents against cancer. Targeted therapies are one of the latest innovative and compelling approaches in cancer treatment. The advances in our understanding of the oncogenic activation of these receptors have been matched by the identification of new structural classes of kinase inhibitors with improved potency, specificity and efficacy. Subsequently, the majority of the kinase inhibitors currently in clinical trials are targeting receptor PTK.
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With the advent of imatinib mesylate a new era in the management of patients with Bcr-Abl positive chronic myelogenous leukemia (CML), gastrointestinal stromal tumors, and myeloproliferative disorders including chronic myelomonocytic leukemia with PDGFRB gene rearrangements and hypereosinophilic syndrome has begun. CML represents a model for the rational design of PTK inhibitors based on the insights into signal transduction pathways. When CML was targeted therapeutically with the selective Bcr-Abl kinase inhibitor imatinib, clinical efficacy data were outstanding with limited toxicity.
This book, in most parts written by leading researchers from the Novartis group, surveys the process used in discovering PTK inhibitors and their use in treating diseases such as cancer. In vivo preclinical models for testing inhibitors and the progress in generating selective low weight inhibitors are discussed. However, the publication reveals the rapid gain of knowledge regarding definition of new targets since with its publication late 2005, it was already outdated. The finding of activating point mutations in JAK2 associated with chronic myeloproliferative disorders, which is certainly one of the most important discoveries in hematology since the description of Bcr-Abl is not covered. Despite comprehensiveness regarding different steps in drug development, several parts of the book are biased towards Novartis compounds, for example the detailed chapter on SRC inhibitors does not mention the most advanced compound within this group BMS-354825 (dasatinib). Despite these minor restrictions, the work provides a comprehensive overview on the function of protein kinases as components of signal transduction pathways, the development of selective PTK inhibitors, the advantages and disadvantages of in vitro and in vivo preclinical models for their testing and the treatment of patients with the most promising and safe inhibitors in the context of clinical trials.
The book is very useful for clinicians treating cancer patients with PTK inhibitors and looking for a deeper insight into the biological background of these compounds and for researchers interested in an overview on the development of PTK inhibitiors covering the relevant pathways, the design of compounds, and preclinical and clinical trials. Obviously, the experience with imatinib contributes to the rapid discovery of new targets and inhibitors.
Considering the size of the book (290 pages), the price of 175 US-$ is too high to reach all researchers interested in the topic. 
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